Final results from the embolden trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma
Clinical trial shows pembrolizumab combined with decitabine improves outcomes in patients with peripheral and cutaneous T-cell lymphoma, highlighting toxicity considerations.
Key Points
To evaluate the safety and efficacy of pembrolizumab in combination with decitabine and pralatrexate in patients with peripheral and cutaneous T-cell lymphoma.
Multicenter, multi-arm phase Ib clinical trial
Three arms: pembrolizumab + pralatrexate, pembrolizumab + pralatrexate + decitabine, and pembrolizumab + decitabine
Evaluation included median age, treatment history, and adverse events
26 patients enrolled, with a median age of 61 years
Overall response rate of 19%, complete response in 10%
Identified recommended phase II doses for decitabine and pralatrexate
Pro-inflammatory cytokines showed significant changes in responders versus non-responders